CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: The antiproliferative activity of TKIs against CD34+ CML cells was confirmed by cell cycle analysis, where treatment with 150 nM dasatinib for 24 hours caused a decrease of cells in S phase (from 33.8% to 28%, *, p ≤ .05) and an increase in G1 phase (from 37.9% to 52.2%, *, p ≤ .05) as shown by representative histogram (Fig. 2A).